FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer T Conroy, P Hammel, M Hebbar, M Ben Abdelghani, AC Wei, JL Raoul, ... New England Journal of Medicine 379 (25), 2395-2406, 2018 | 2764 | 2018 |
Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer P Laurent-Puig, A Cayre, G Manceau, E Buc, JB Bachet, T Lecomte, ... Journal of clinical oncology 27 (35), 5924-5930, 2009 | 879 | 2009 |
Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II G Malamut, P Afchain, V Verkarre, T Lecomte, A Amiot, D Damotte, ... Gastroenterology 136 (1), 81-90, 2009 | 450 | 2009 |
Detection of free‐circulating tumor‐associated DNA in plasma of colorectal cancer patients and its association with prognosis T Lecomte, A Berger, F Zinzindohoué, S Micard, B Landi, H Blons, ... International journal of cancer 100 (5), 542-548, 2002 | 411 | 2002 |
Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy T Lecomte, JM Ferraz, F Zinzindohoué, MA Loriot, DA Tregouet, B Landi, ... Clinical Cancer Research 10 (17), 5880-5888, 2004 | 336 | 2004 |
Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis D Rosmarin, C Palles, D Church, E Domingo, A Jones, E Johnstone, ... Journal of Clinical Oncology 32 (10), 1031-1039, 2014 | 281 | 2014 |
Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy T Lecomte, B Landi, P Beaune, P Laurent-Puig, MA Loriot Clinical Cancer Research 12 (10), 3050-3056, 2006 | 261 | 2006 |
Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly … T Aparicio, JL Jouve, L Teillet, D Gargot, F Subtil, V Le Brun-Ly, J Cretin, ... Journal of Clinical Oncology 31 (11), 1464-1470, 2013 | 244 | 2013 |
Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial T Conroy, F Castan, A Lopez, A Turpin, MB Abdelghani, AC Wei, E Mitry, ... JAMA oncology 8 (11), 1571-1578, 2022 | 201 | 2022 |
Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study A Zaanan, L Costes, M Gauthier, D Malka, C Locher, E Mitry, D Tougeron, ... Annals of Oncology 21 (9), 1786-1793, 2010 | 197 | 2010 |
Unicancer GI PRODIGE 24/CCTG PA. 6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected … T Conroy, P Hammel, M Hebbar, M Ben Abdelghani, AC Wei, JL Raoul, ... Journal of Clinical Oncology 36 (18_suppl), LBA4001-LBA4001, 2018 | 196 | 2018 |
Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort A Portal, S Pernot, D Tougeron, C Arbaud, AT Bidault, ... British journal of cancer 113 (7), 989-995, 2015 | 194 | 2015 |
Malnutrition is high and underestimated during chemotherapy in gastrointestinal cancer: an AGEO prospective cross-sectional multicenter study A Attar, D Malka, JM Sabaté, F Bonnetain, T Lecomte, T Aparicio, ... Nutrition and cancer 64 (4), 535-542, 2012 | 180 | 2012 |
Efficacy of adjuvant chemotherapy in colon cancer with microsatellite instability: a large multicenter AGEO study D Tougeron, G Mouillet, I Trouilloud, T Lecomte, R Coriat, T Aparicio, ... Journal of the National Cancer Institute 108 (7), djv438, 2016 | 178 | 2016 |
RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study JB Bachet, O Bouché, J Taieb, O Dubreuil, ML Garcia, A Meurisse, ... Annals of Oncology 29 (5), 1211-1219, 2018 | 167 | 2018 |
Refractory coeliac sprue is a diffuse gastrointestinal disease V Verkarre, V Asnafi, T Lecomte, NP Mariaud-de Serre, M Leborgne, ... Gut 52 (2), 205-211, 2003 | 161 | 2003 |
Chromoendoscopic colonoscopy for detecting preneoplastic lesions in hereditary nonpolyposis colorectal cancer syndrome T Lecomte, C Cellier, T Meatchi, JP Barbier, PH Cugnenc, R Jian, ... Clinical Gastroenterology and Hepatology 3 (9), 897-902, 2005 | 155 | 2005 |
Second‐line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine‐platinum combination: A large multicenter study by the Association des Gastro … B Brieau, L Dahan, Y De Rycke, T Boussaha, P Vasseur, D Tougeron, ... Cancer 121 (18), 3290-3297, 2015 | 141 | 2015 |
Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy N Ceze, G Thibault, G Goujon, J Viguier, H Watier, E Dorval, T Lecomte Cancer chemotherapy and pharmacology 68, 1305-1313, 2011 | 141 | 2011 |
Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 … S Kubicka, R Greil, T André, J Bennouna, J Sastre, E Van Cutsem, ... Annals of oncology 24 (9), 2342-2349, 2013 | 136 | 2013 |